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Background: One of the challenging problems of current radio-chemotherapy is recurrence and metastasis of
cancer cells that survive initial treatment. We propose that one of the unwanted effects of radiochemotherapy is
the release from damaged (“leaky”) cells of nucleotides such as ATP and UTP that exert pro-metastatic functions
and can directly stimulate chemotaxis of cancer cells.
Methods: To address this problem in a model of human lung cancer (LC), we employed several complementary
in vitro and in vivo approaches to demonstrate the role of extracellular nucleotides (EXNs) in LC cell line metastasis and
tumor progression. We measured concentrations of EXNs in several organs before and after radiochemotherapy. The
purinergic receptor agonists and antagonists, inhibiting all or selected subtypes of receptors, were employed in in vitro
and in vivo pro-metastatic assays.
Results: We found that EXNs accumulate in several organs in response to radiochemotherapy, and RT-PCR analysis
revealed that most of the P1 and P2 receptor subtypes are expressed in human LC cells. EXNs were found to induce
chemotaxis and adhesion of LC cells, and an autocrine loop was identified that promotes the proliferation of LC cells.
Most importantly, metastasis of these cells could be inhibited in immunodeficient mice in the presence of specific
small molecule inhibitors of purinergic receptors.
Conclusions: Based on this result, EXNs are novel pro-metastatic factors released particularly during
radiochemotherapy, and inhibition of their pro-metastatic effects via purinergic signaling could become an important
part of anti-metastatic treatment.
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There are well-known side effects of chemotherapy and
radiotherapy, mainly due to the toxicity-related impaired
function of vital organs [1, 2]. However, in addition, these
therapies induce the unwanted expression and release of
several pro-metastatic factors that create a pro-metastatic* Correspondence: mzrata01@louisville.edu
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We propose the novel concept that toxic damage in
various organs leads to an upregulation of the expression
and activity of several factors in “bystander” tissues,
including extracellular nucleotides (EXNs), which pro-
vide chemotactic signals to cancer cells that survived the
initial treatment. We propose that this mechanism plays
an important role in the metastasis of cancer cells and
indicates the need to develop efficient anti-metastatic
drugs that work in combination with, or follow, standardicle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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induced spread of tumor cells [1, 3–5].
Nucleotides leaking through the membranes of dam-
aged cells or released through specific pathways include
purine nucleotides and nucleosides (e.g., ATP, ADP, AMP,
adenosine) as well as pyrimidine nucleotides (e.g., UTP,
UDP), which signal through purinergic receptors
expressed in almost every tissue [6]. There are both nu-
cleoside- and nucleotide-activated receptors, which belong
to different receptor families and are distinguishable by
their pharmacological properties. While P1 receptors,
which are divided into A1, A2A, A2B, and A3 subtypes, re-
spond to adenosine and its analogues, P2 receptors are
activated by ATP and/or other nucleotides. P2 receptors
are further subdivided into ionotropic (P2X) and metabo-
tropic (P2Y) receptors, based on structural characteristics
[7, 8]. Ionotropic P2X receptors are assembled in a tri-
meric form as homo- or heteromers consisting of the sub-
units designated P2X1–7. P2X receptor channels are
activated by ATP, which opens the channel to allow the in-
flux of Ca2+, Na+, and K+. The mammalian metabotropic
P2 receptor family contains eight different subtypes,
denoted P2Y1, 2, 4, 6, 11, 12, 13, and 14 [7, 8].
Nucleotides may also be released from cells in re-
sponse to certain stimulatory agents and affect the cell
in an autocrine/paracrine manner. For example, the mi-
gration of leucocytes in response to analpylatoxin C5a is
potentiated by the release of ATP at the leading edge of
migrating cells [9]. The availability and lifetime of re-
leased ATP in a controlled manner for autocrine or
paracrine stimulation of purinergic receptors is con-
trolled by a highly efficient enzymatic cascade, including
processing that degrades nucleotides (e.g. ATP, ADP, and
AMP), finally yielding nucleosides (e.g. adenosine) and
thereby regulating activity levels of the various P2 and
P1 receptors [10]. It has been reported that, while the
interstitial ATP in normal tissues attains a concentration
of up to 1000 nM, the intratumoral ATP concentration
can be as much as 103–104 fold higher [11].
Taking into consideration the possibility that EXNs
affect the behavior of LC cells, we became interested
in their role in progression of this tumor. We ob-
served that EXNs accumulate in several murine or-
gans in response to radiochemotherapy and that most
of the functional P2X, P2Y, and P1 receptor subtypes
are expressed in human LC cells. EXNs were found
to modulate the pro-metastatic behavior of LC cells,
and their metastasis could be inhibited in immunode-
ficient mice in the presence of specific small molecule
inhibitors of purinergic receptors. Based on these
findings, it is clear that EXNs are novel pro-metastatic
factors and that inhibition of their pro-metastatic effects
via purinergic signaling could become an important part
of anti-metastatic treatment.Methods
Cell lines
We used several human lung cancer cell lines (obtained
from the American Type Culture Collection, Manassas,
VA), including both non-small cell lung cancer (NSCLC;
A549, HTB177, HTB183, and CRL5803) and small cell
lung cancer (SCLC; CRL2062 and CRL5853) cell lines.
NSCLC cells were cultured in Roswell Park Memorial
Institute (RPMI) medium 1640, containing 10 % fetal bo-
vine serum (FBS), 100 U/ml penicillin, and 10 μg/ml
streptomycin. CRL2062 cells were maintained in
Waymouth’s MB 752/1 medium containing 10 % FBS,
100 U/ml penicillin, and 10 μg/ml streptomycin.
CRL5853 cells were cultured in DMEM:F12 medium sup-
plemented with 5 % FBS, 0.005 mg/ml insulin, 0.005 mg/
ml transferrin, 30 nM sodium selenite (ITS, Lonza, Allen-
dale, NJ), 10 nM hydrocortisone (Sigma-Aldrich, St. Louis,
MO, USA), 10 nM beta-estradiol (Sigma-Aldrich),
4 mM L-glutamine, 100 U/ml penicillin, and 10 μg/ml
streptomycin. All cells were cultured in a humidified
atmosphere of 5 % CO2 at 37 °C, and the media were
changed every 48 h.
Preparation of conditioned media
Pathogen-free C57BL6 mice were purchased from the
National Cancer Institute (Frederick, MD, USA), allowed
to adapt for at least 2 weeks, and used for experiments
at age 7–8 weeks. Animal studies were approved by the
Animal Care and Use Committee of the University of
Louisville (Louisville, KY, USA). Mice were irradiated
with 250, 500, 1000, or 1500 cGy. Twenty-four hours
later, bone marrow and plasma were isolated. Condi-
tioned medium (CM) was obtained by 1-h incubation of
BM in RPMI at 37 °C. After centrifuging, the supernatant
was used for further experiments. In studies with the che-
motherapeutic agent vincristine, mice were injected intra-
peritoneally with 0.9 % NaCl with (0.5 mg/kg or 2 mg/kg)
or without vincristine. Twenty-four hours later, organs
were isolated, and CM was prepared as described above.
Chemotaxis assay
Chemotaxis assays were performed in a modified
Boyden’s chamber with 8-μm polycarbonate membrane
inserts (Costar Transwell; Corning Costar, Lowell, MA,
USA) as described previously [3, 4]. In brief, cells de-
tached with 0.25 % trypsin were made quiescent by incu-
bation for 1–3 h in appropriate medium (RPMI,
DMEM-F12, or Waymouth’s MB 752/1), supplemented
with 0.5 % (NSCLC) or 0.2 % (SCLC) bovine serum al-
bumin (BSA). The cells were then seeded into the upper
chamber of an insert (pretreated with 1 % gelatin) at a
density of 3.5 × 104 (NSCLC) or 10 × 104 (SCLC) in
110 μl. The lower chamber was filled with pre-warmed
medium containing test reagents. All nucleotides
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ADP; adenosine monophosphate, AMP; adenosine; uri-
dine triphosphate, UTP; guanosine triphosphate, GTP;
thymidine triphosphate, TTP; cytidine triphosphate,
CTP) were obtained from Sigma-Aldrich. Medium sup-
plemented with BSA was used as a negative control. In
some experiments, cells were pretreated with the P2 re-
ceptors inhibitor iso-PPADS (Tocris, Minneapolis, MN),
the A1 receptor agonist PSB63 (Tocris), the A2A receptor
antagonist ANR94 (Tocris), the A2B receptor antagonist
PSB603 (Tocris), the A3 receptor antagonist MRS3777
(Tocris) or the stimulator ivermectin (Sigma-Aldrich)
for 15 min at 37 °C. Inhibitors were also added to the
lower chambers and were present throughout the ex-
periment. In experiment with apyrase, apyrase (Sigma)
was added to lower chamber together with HGF.
After 24 h, the inserts were removed from the
Transwell supports. The cells that had not migrated
were scraped off with cotton wool from the upper
membrane, and the cells that had transmigrated to
the lower side of the membrane were fixed and
stained with HEMA 3 (manufacturer’s protocol, Fisher
Scientific, Pittsburgh, PA) and counted on the lower
side of the membrane using an inverted microscope.
Adhesion assay to fibronectin
Cells were made quiescent for 3 h with appropriate
medium containing BSA and incubated with nucleotides
for 10 min. Subsequently, cell suspensions (5 × 103/
100 μL) were added directly to 96-well plates coated with
fibronectin and incubated for 5 min at 37 °C. The wells
were previously coated with fibronectin (10 μg/ml) over-
night at 4 °C and blocked with 0.5 % BSA for 1 h before
the experiment. Following incubation, the plates were vig-
orously washed three times to remove non-adherent cells,
and the number of adherent cells was counted using an
inverted microscope.
Real-time quantitative reverse-transcription PCR
Total RNA was isolated from LC cells with the RNeasy kit
(Qiagen, Valencia, CA). Human lung RNA was obtained
from Ambion (Austin, TX). The RNA was reverse tran-
scribed with MultiScribe reverse transcriptase, oligo(dT),
and random-hexamer primer mix (Life Techonologies,
Foster City, CA). Quantitative assessment of mRNA levels
was done by real-time reverse transcription PCR (qRT-
PCR) on an ABI 7500 Fast instrument with Power SYBR
Green PCR Master Mix reagent. Real-time conditions
were as follows: 95 °C (15 s), 40 cycles at 95 °C (15 s), and
60 °C (1 min). According to melting point analysis, only
one PCR product was amplified under these conditions.
The relative quantity of a target, normalized to the
endogenous β2-microglobulin gene as control and
relative to a calibrator (normal lung tissue), isexpressed as 2−ΔΔCt (fold difference), where Ct is the
threshold cycle, ΔCt = (Ct of target genes) − (Ct of the
endogenous control gene, β2-microglobulin), and
ΔΔCt = (ΔCt of lung cancer cell line sample cDNA
for target gene) − (ΔCt of normal lung tissue cDNA
for the target gene). All primers that were used for
qRT-PCR are listed in Additional file 1: Table S1.
Flow cytometry
For measuring A2B expression cells were detached using
non-enzymatic reagent (CellStripper, Corning), followed
by 2 h incubation in appropriate medium with 0.5 %
BSA. Next cells were washed with PBS, fixed by 15 min
incubation at 4 °C in BD Cytofix/Cytoperm solution (BD
Biosciences, Franklin Lakes, NJ, USA), washed again and
incubated for 30 min in 0.5 % BSA in PBS. Cells were
stained with primary rabbit polyclonal anti-A2B
antibody (1:25, Bioss Inc, Woburn, MA, USA) for 1 h at
37 °C. Than cells were washed and incubated with sec-
ondary antibody Alexa Fluor 488 goat anti-rabbit (1:100,
Life Technologies). Cells were then analyzed using the
LSR cell cytometer (BD Biosciences). For all other recep-
tors cells were detached and mechanically dissociated to
a single cell suspension using TrypLE™ Express (Life
Technologies) for 1 min at room temperature, passed
through a 40 μm cell strainer and then washed twice
with phosphate-buffered saline (PBS). Cells were subse-
quently fixed with 4 % (PBS) for 30 min at RT, washed
and incubated for 30 min in a blocking solution contain-
ing 0.05 % Triton X-100, 0,05 % Tween-20 and 5 % FBS
in PBS. Staining with primary antibodies was performed
after 2 h incubation with primary antibodies: rabbit poly-
clonal anti-P2X4 (1:200, Santa Cruz Biotech, Dallas, TX,
USA), rabbit polyclonal anti-P2X7 (1:200, Aviva Systems
Biology, Corp., San Diego, CA, USA), goat polyclonal
anti-P2Y1 (1:200, Santa Cruz Biotech), rabbit polyclonal
anti-P2Y12 (1:500, Alomone, Jerusalem, Israel). Cells
then were washed and incubated for 40 min with Alexa
Fluor 488 donkey anti-rabbit (1:1,000, Life Technologies)
or Alexa Fluor 488 donkey anti-goat (1:1,000, Life
Technologies) secondary antibodies. Cells were analyzed
with the AttuneVR cytometer (Life Technologies). The
analysis of the data was performed using the FlowJo
7.2.5 or 7.6.3 software (FLOWJO, Ashland, OR, USA).
Unstained cells and cells incubated with isotype control
were used as controls.
Mean relative of fluorescence intensity analysis is pre-
sented as a value of mean of fluorescence intensity for
stained cells divided by mean of fluorescence intensity
obtained for control cells.
Cell proliferation
Cells were seeded in culture flasks at an initial density of
1.25 × 104 cells/cm2 (NSCLC) or 6 × 104 cells/cm2
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medium supplemented with 0.5 % BSA, and the cells
were cultured in the presence or absence of nucleotides.
Full medium (with FBS) was treated as a positive con-
trol. The cell number was calculated at 24, 48, and 72 h
after the change of medium. At the indicated time
points, cells were harvested from the culture plates by
trypsinization and counted using Trypan Blue and a
Neubauer chamber.
Phosphorylation of intracellular pathway proteins
The HTB177 and CRL5803 cell lines were kept over-
night or 6 h, respectively, in medium containing 0.5 %
BSA to render the cells quiescent. The cells were then
stimulated with nucleotides at 37 °C for 5 min, then
lysed for 20 min on ice in RIPA lysis buffer containing
protease and phosphatase inhibitors (Santa Cruz
Biotech, Santa Cruz, CA). The extracted proteins were
separated on a 12 % SDS-PAGE gel and transferred to a
PVDF membrane. Phosphorylation of the serine/threo-
nine kinase AKT (phospho-AKT473) and p44/42
mitogen-activated kinase (phospho-p44/42 MAPK) was
detected by rabbit and mouse antibodies (Cell Signaling,
Danvers, MA, USA), respectively, with HRP-conjugated
goat anti-rabbit and anti-mouse secondary antibodies
(Santa Cruz Biotech). Equal loading in the lanes was eval-
uated by stripping the blots and reprobing with anti-p42/
44 MAPK monoclonal antibody (clone no. 9102, Cell
Signaling) and anti-AKT polyclonal antibody (Cell Signal-
ing). The membranes were developed with enhanced
chemiluminescence (ECL) reagent (Amersham Life
Sciences, Arlington Heights, IL), dried, and subsequently
exposed to film (Hyperfilm, Amersham Life Sciences).Calcium measurements by microfluorimetry
Cell suspensions (5 × 104/100 μL) were seeded onto a
black 96-well, clear-bottom plate in appropriate medium
and cultured until reaching 80–90 % confluence. The
intracellular calcium concentration transient was mea-
sured using the FlexStation Calcium 4 Assay Kit
(Molecular Devices Corp.), as reported elsewhere [12].
To explore the mechanism of agonist efficacy, the indir-
ect fluorescence were determined using a FlexStation III
plate reader (Molecular Devices Corp., Sunny Valley,
CA). Briefly, the cells were incubated for 1 h at 37 °C
with the calcium indicator solution containing 2.5 mM
probenecid in a 200-μL final volume per well. The fluo-
phore was excited at 485 nm, and the emitted fluores-
cence was detected at 525 nm. Changes in free
intracellular calcium concentration ([Ca2+]i) were deter-
mined by subtracting the minimum fluorescence intensity
from the maximum fluorescence intensity (Fmax–Fmin),
normalized by the baseline resting state.Quantitation of ATP, UTP and adenosine
The ATP levels secreted by cultured LC cells were mea-
sured using the Adenosine 5′-triphosphate Biolumines-
cent Somatic Cell assay kit (Sigma-Aldrich), according
to the manufacturer’s instructions. Briefly, cells were
seeded into black 96-well microplates with transparent
bottoms, and the light emitted by luciferase activity was
detected using a FlexStation III plate reader (Molecular
Devices Corp., Sunny Valley, CA), with the light inten-
sity proportional to ATP concentration. The ATP level
in bone marrow (BM), conditioned medium from BM,
and plasma were measured using the ATP Colorimetric/
Fluorometric Assay Kit and Deproteinizing Sample Prep-
aration Kit (BioVision, Milpitas, CA, USA), according to
the manufacturer protocol. Fluorescence analysis was
performed with Ex/Em set at 535/585 nm. Adenosine
level was measured using Adenosine Fluorymetic Assay
Kit (BioVision) and UTP level was measured using UTP
ELISA Kit (MyBio Source, San Diego, CA, USA) accord-
ing to the manufacturers’ protocols.
Bone marrow cell lysates and conditioned media were
obtained by flushing the bone marrow tibia and femur
cavities and resuspending cells in 3 ml of RPMI medium.
Cells suspensions were than centrifuged (680 × g,
10 min, 4 °C) and supernatants were collected and
employed in experiments as conditioned media. Bone
marrow cells were than washed with PBS, counted using
Tuerk solution and cells pellets were fast frozen and
stored in −80 °C. To obtained cell lysates frozen pellets
were resuspended in 200 μl of PBS cells and subjected
to ultrasonication 10 times (1 s) followed by centrifuga-
tion at 20,000 × g for 10 min, 4 °C to remove cell debris.
Transplant of LC cells into immunodeficient mice
To study the effects of the pharmacological inhibition of
P2X or A2b signaling on the metastasis of lung cancer
in vivo, HTB177 cells were pretreated with iso-PPADS
(100 μM), PSB603 (1 μM), or vehicle alone for 1 h. The
cells were then washed and injected intravenously (2.5 ×
106 per mouse) into severe combined immunodeficient
(SCID)-Beige inbred mice (five mice per group) that were
either untreated (control) or previously irradiated with
1000 cGy for 24 h. Marrows, livers, and lungs were re-
moved 48 h after injection of these cells, and the presence
of LC cells (i.e., murine–human chimerism) was evaluated
as the difference in the level of human α-satellite DNA ex-
pression. DNA was amplified in the extracts isolated from
BM-, liver-, and lung-derived cells using real-time PCR.
Briefly, DNA was isolated using the QIAamp DNA kit
(Qiagen). Detection of human satellite and murine β-actin
DNA levels was conducted using real-time PCR and an
ABI Prism 7500 Sequence Detection System. A 25-μl reac-
tion mixture containing 12.5 μl SYBR Green PCR Master
Mix, 300 ng DNA template, 5′-ACC ACT CTG TGT
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TCA AAA GGA GTG T-3′ reverse primers for α-satellite
DNA, and 5′-TTC AAT TCC AAC ACT GTC CTG TCT
-3′ forward and 5′- CTG TGG AGT GAC TAA ATG
GAA ACC -3′ reverse primers for β-actin DNA was used.
The Ct value was determined as before. The number of
human cells present in the murine organs (the degree of
chimerism) was calculated from the standard curve
obtained by mixing different numbers of human cells with
a constant number of murine cells.Statistical Analysis
Statistical analysis of the data was done using T–test (for
data with normal distribution) or Whitney–Mann test
(data without normal distribution) with p < 0.05 consid-
ered significant or one way ANOVA with Bonferroni
post hoc p ≤ 0.05 (calcium measurements and analysis of
ATP in culture medium).A
C D
B
Fig. 1 The level of EXNs increases after irradiation or chemotherapy, and E
a and b. The level of ATP, UTP and adenosine in BM lysate (Panel a) and C
(0–1500 cGy) or vincristine administration (0.5–2 mg/kg). Measurements we
adenosine) independent isolations. Each analysis was performed in duplica
line to ATP (left) and hepatocyte growth factor (HGF) at physiological (L; 0.
Panel d. Optimal doses of the tested nucleotides based on chemotactic do
ADP, AMP, and adenosine. Panel e. Chemotaxis of NSCLC and SCLC cells in re
of HGF (10 ng/ml). Experiment was performed at least three times. Panel f. Ad
ADP, AMP, and adenosine. Experiment was performed three times. *p < 0.05Results
The ATP level increases in response to irradiation and
chemotherapy, and EXNs induce migration and adhesion
of lung cancer cell lines
In our previous work we proposed that a side effect of ra-
diochemotherapy is the induction of a pro-metastatic en-
vironment due to upregulation of several chemokines and
growth factors as well as bioactive lipids [3, 4, 13]. Here
we tested the hypothesis that damage caused by radioche-
motherapy treatment may also release pro-metastatic
EXNs from damaged “leaky” bystander cells [1]. To test
this possibility, we analyzed the level of ATP in superna-
tants flushed from bone marrow (BM) cavities as well as
in media conditioned by cultured BM cells isolated from
untreated, irradiated, or vincristine-treated animals.
As shown in Fig. 1a and b, we observed an increase in
ATP, UTP and adenosine level in BM after irradiation or
vincristine administration. Moreover, this increase in
level of ATP, UTP and adenosine correlates with lowerE
F
XNs induce migration and adhesion of lung cancer cell lines. Panels
M from BM cells (Panel b) prepared from animals 24 h after irradiation
re performed for samples from three (ATP) or two (UTP and
tes. Panel c. Dose-dependent chemotactic response of the HTB177 cell
3 ng/ml) or supraphysiological (H; 10 ng/ml) concentrations (right).
se-dependent responses of lung cancer cell lines tested with ATP,
sponse to ATP, ADP, AMP, and adenosine and a supraphysiological dose
hesion of NSCLC and SCLC cells to fibronectin after stimulation with ATP,
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tion (Additional file 2: Figure S1A) suggesting that ana-
lyzed nucleotides and nucleoside are released from dying
cells. Interestingly we did not observe significant
changes in the level of ATP, UTP and adenosine in
murine plasma (Additional file 2: Figure S1b).
Next, we tested the responsiveness of human LC
cells to a chemotactic gradient of EXNs. Figure 1c
shows an example of the migration of HTB177 cells
in response to increasing levels of ATP (left panel)
compared with high and low (physiological) concen-
trations of a known chemoattractant of LC cells, hep-
atocyte growth factor (HGF, right panel). Based on
similar experiments, we established the optimal dose
of EXNs, which was subsequently employed in our
studies (Fig. 1d) unless otherwise indicated.
Figure 1e shows that all NSCLC cell lines responded
by chemotaxis to ATP, ADP, AMP, and adenosine in a
manner similar to a high dose of HGF (upper panel).
We observed a similar responsiveness of SCLC cell lines
to stimulation with nucleotides (lower panel). The
chemotactic response of LC cells to nucleotidesA D
B
C
Fig. 2 Lung cancer cell lines express functional P1 and P2 receptors. Panel
receptors in human lung cancer cell lines. Normal lung tissue RNA (h lung)
duplicates. Panel d. Flow Cytometry analysis of A2B, P2X4, P2X7, P2Y1, P2Y1correlated with increased adhesion of these cells to fi-
bronectin after stimulation with EXNs (Fig. 1f ). To our
surprise lung cancer cell lines turned out to be highly
sensitive to ADP exposure and responded by enhanced
migration and adhesion to relatively low concentration
of this nucelotide (20 nM) (Fig. 1e and f). Of note, in
parallel experiments we also observed that several other
nucleotides, such as TTP, UTP, CTP, and GTP, chemoat-
tract and stimulate adhesion of human LC cells
(Additional file 3: Figure S2a, b).
Lung cancer cell lines express functional P1 and
P2 receptors
Since EXNs signal through cell membrane receptors, we
employed real time-PCR to assess the expression of P1
and P2 receptors in the NSCLC and SCLC cell lines
employed in our studies. We observed that, out of all
the P1 receptors, the NSCLC cell lines express the ad-
enosine A2B receptor at a high level, although it is not
expressed by the SCLC cell lines (Fig. 2a). Most of the
LC cell lines evaluated in our study also expressed the
P2X (Fig. 2b) and P2Y receptors (Fig. 2c). In particular,s a–c. qRT-PCR analysis of P1 (Panel a), P2X (Panel b), and P2Y (Panel c)




Fig. 3 P1 and P2 receptors are functional in lung cancer cell lines. Panels a-b. Phosphorylation of p42/44 MAPK and AKT in the human NSCLC cell line
HTB177 (Panel a) and the SCLC cell line CRL5853 (Panel b) after being stimulated for 5 min with the indicated nucleotides. The experiment was
repeated twice, with similar results, and representative western blots are shown. Right panels show quantitative analysis of MAPKp42/44 and AKT
phosphorylation. Panel c. Intracellular calcium measurments in lung cancer cell lines in response to 100 μM ATP (left top) or 1 mM ATP (right top),
100 μM Bz-ATP (left bottom), or 100 μM adenosine (right bottom). Analysis was performed at least 3 times in triplicates. Values are mean ± SEM
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lines employed in our studies. To confirm presence of
receptors on cell surface, we performed flow cytometry
analysis of A2B, P2X4, P2X7, P2Y1 and P2Y12 receptors
and we were able to detect expression of analyzed recep-
tors in all tested cell lines (Fig. 2d). We performed also
mean relative of fluorescence intensity (MRFI) analysis
(Additional file 4: Figure S3) of receptor expression. Level
of receptor expression by FACS corresponded in majority
of cases with our qRT-PCR data (Fig. 2a-c). However, as it
is known expression of given protein at mRNA level does
not always correlate with translated protein. Therefore,
some of differences in expression level an RNA and pro-
tein level observed could be explained for example by dif-
ferent turnover and half-life of the mRNA and
corresponding protein in different cell lines.
To better address the functionality of purinergic recep-
tors, we examined whether purinergic nucleotides and
nucleosides induce signaling pathways involved in cell
migration and adhesion [14, 15]. As shown in Fig. 3
panels a and b, ATP, ADP, AMP, and adenosine induced
MAPK p42/44 and AKT phosphorylation in the NSCLC
cell line HTB177 and the SCLC cell line CRL5853. The
left side of these figures shows a western blot, and the
right side shows the corresponding densitometry mea-
surements. Of note, we also observed that other nucleo-
tides, such as UTP, CTP, GTP, and TTP, induced
phosphorylation of MAPKp42/44 and AKT in HTB177
and CRL5853 LC cell lines (Additional file 5: Figure S4).Fig. 4 P1 receptors regulate the migratory properties of lung cancer cells. Th
Migration of cells acros Transwell membrane in response to adenosine in the
antagonist), PSB603 (an A2b receptor antagonist), and MRS3777 (an A3 recep
results. All values are mean ± SD with *p < 0.05Next, since P2X and P2Y receptor stimulation may re-
sult in [Ca2+]i increase, we measured whether LC cells
show calcium concentration transients in response to P2
receptor agonist ATP and Bz-ATP, which is a P2X7 re-
ceptor agonist that is 5–30 times more potent than ATP
and can also stimulate all P2X receptors. We found that
all cell lines tested responded by calcium signaling upon
stimulation by ATP (Fig. 3c upper panel) as well as by
Bz-ATP (Fig. 3c lower left panel), and their responsive-
ness varied with the cell line tested. Interestingly, while
expression of the P2X7 receptor was low in LC cell lines
(Fig. 2b), Bz-ATP turned out to be a potent stimulator of
calcium signaling, probably due to stimulation of all P2X
receptors. Of note, UTP, a P2Y2 and P2Y4 receptor agon-
ist, also stimulated intracellular calcium mobilization
(Additional file 3: Figure S2c). As shown in the lower right
panel of Fig. 3c, adenosine also induced intracellular cal-
cium fluxes in human LC cell lines. All these data confirm
that human lung cancer cells express functional
purinergic receptors.
Small molecule inhibitors of purinergic receptors
modulate the chemotactic responsiveness of LC cells in a
receptor-dependent manner
To test the efficacy of small molecule inhibitors of P1 re-
ceptor signaling in LC cells, we tested the effect of dif-
ferent P1 receptor inhibitors using the A549 cell line,
which expresses adenosine A1, A2A, and A2B receptors at
the highest levels of all the analyzed cell lines but note effect of adenosine receptor inhibitors on the migration of A549 cells.
presence of PSB36 (an A1 receptor antagonist), ANR 94 (an A2a receptor




Fig. 5 P2 receptors regulate the migratory properties of lung cancer cells. Panel a The effect of iso-PPADS on the migration of A549 (left) and
HTB177 (right) cells across Transwell membranes in response to adenosine. HGF (10 ng/ml) was used as positive control. The experiment was
done three times. *p < 0.05. Panel b. The effect of the P2X7R inhibitor A438079 on the migration of HTB177 (left) and HTB183 (right) cells acros
Transwell membrane in response to ATP. The experiment was done three times. *p < 0.05. Panel c. The effect of the P2X7 inhibitor A438079 on
intracellular calcium measurements in lung cancer cell lines in response to 100 μM ATP. Analysis was performed at least 3 times in triplicates
*p < 0.05. Panel d. The effect of pretreatment of cells with ivermectin (10 μM) on Transwell membrane migration in response to ATP. The
experiment was done three times. *p < 0.05
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(Fig. 4). We found that A1 (PSB36), A2A (ANR94), and,
in particular, A2B (PSB603) receptor antagonists partially
inhibited migration of A549 cells in response to adeno-
sine, which is a P1 receptor agonist. Of note, the A2B re-
ceptor was found to be highly expressed by these cells.
At the same time, as expected, since the A3 receptor is
not expressed by A549 cells, we did not observe any ef-
fect on the migration of these cells across Transwell
membranes in response to adenosine in the presence of
the A3 receptor antagonist MRS3777 (Fig. 4 lower right
panel). Interestingly, we also found that sensitivity of LC
cells to PSB603 is correlated with the level of expression
of A2B receptor. Accordingly, inhibition of migration of
HTB177 cells which express lower level of A2B receptor
than A549 was already observed in presence of 1 μM
PSB603 (data not shown).
Based on our observation that the P2X receptors are
involved in migration of breast cancer [16], we became
interested in whether these receptors play a role in the
migration of LC cells. At first, we used a nonspecific an-
tagonist of all P2X receptors, iso-PPADS, and observed
its inhibitory effect on the chemotaxis of A549 and
HTB177 cells in response to the P2X agonist, ATP
(Fig. 5a). At the same time, in control experiments we
did not observe any reduction in the chemotactic re-
sponse of LC cells to HGF, which confirmed inhibitor
specificity (Fig. 5a).
Since, as reported in the literature, the P2X7 receptor
stimulates cell migration [17, 18], we employed an an-
tagonist of the P2X7R, A438079, in chemotaxis assays of
LC cell lines in response to ATP. As shown in Fig. 5b,
A438079 inhibited migration of HTB177 and HTB183 in
a P2X7-dependent manner. This result corroborated the
results of the intracellular calcium release experiments
(Fig. 5c) as did the P2X7 expression level (Fig. 2b).
Next, since, as shown in Fig. 2b, P2X4 receptors is
expressed at the highest level in LC cell lines com-
pared with other P2X receptors, we tested its respon-
siveness to an ATP gradient in the presence of
ivermectin, which increases the response of the P2X4
receptor to ATP stimulation, as previously described
[19, 20]. Figure 5d shows that A549 and HTB183
cells, which show the highest expression of P2X4, re-
spond more robustly to an ATP gradient in the pres-
ence of ivermectin. At the same time, as expected in
control experiments, ivermectin did not affect the mi-
gration of LC cells in response to HGF.
Autocrine release of nucleotides can play a role in the
migration of cells in response to HGF and stimulate
their proliferation
Based on findings in the literature [21–23], we tested
whether EXNs affect proliferation of LC cells. However,to our surprise, none of the tested nucleotides was able
to stimulate or inhibit proliferation of these cells at con-
centrations sufficient to stimulate their migration (data
not shown). On the other hand, it has been reported that
nucleotides may be released from cells in response to
certain factors (e.g., the complement cascade cleavage
fragment C5a) and stimulate the cells’ responsiveness to
autocrine/paracrine signaling axes [9].
As shown in Fig. 6a, we were able to detect ATP in
conditioned media harvested from all tested LC cell
lines. Interestingly, we also found that HGF, which is a
chemoattractant for LC cells, enhanced secretion of ATP
by LC cells. This observation requires further study to
determine whether some of the migratory effects of
peptide-based chemoattractants could be related to the
costimulatory effect of autocrine-secreted nucleotides, as
reported for the C5a effect on leucocyte migration [9].
To check whether increased migration in response to
HGF might be related to ATP release, we performed
chemotaxis assay in the presence or absence of apyrase,
which hydrolyzes ATP. We found that migration of
HTB177 to HGF was inhibited when apyrase was added
to the lower chamber (Additional file 6: Figure S5),
which confirms potential role of ATP in HGF induced
migration of lung cancer cells.
Finally, taking into consideration the potential effect of
autocrine EXN axes in the proliferation of LC cells, we
exposed LC cells to the P2X inhibitor isoPPADs and to
caffeine, a non-specific inhibitor of the P1 receptors,
alone or in combination (Fig. 6b). We found an inhibi-
tory effect of the inhibition of P1 and P2X signaling on
the proliferation of LC cells, which was most
pronounced for the SCLC cell lines.
Pretreatment of LC cells with antagonist of A2B or P2X
receptor decreases adenosine- and ATP-dependent
metastatic spread of lung cancer cells
Finally, we tested whether inhibition of A2B receptor in
HTB177 cells by PSB603 affects the metastatic spread
(seeding efficiency) of these cells in vivo to tissues dam-
aged by irradiation. To address this issue, HTB177 cells
were exposed to PSB603 for 1 h, washed, and injected
into control non-irradiated and 1000-cGy-irradiated
SCID/beige immunodeficient mice (Fig. 7a). We found
that irradiation increases the seeding efficiency of
HTB177 cells to liver, lung, and BM and that this effect
was significantly decreased in the case of liver and BM
after pretreatment of HTB177 cells with PSB603 (Fig. 7a).
A similar experiment was performed with cells pre-
treated with the P2X inhibitor iso-PPADS. We observed
significantly reduced seeding of HTB177 cells pretreated
with iso-PPADS (Fig. 7b), which corroborates the obser-
vation that the ATP level is highly elevated in irradiated
tissues (Fig. 1a,b).
AB
Fig. 6 The involvement of HGF-mediated release of nucleotides from LC cells and the role of autocrine ATP loops in LC cell proliferation. Panel
a. ATP levels in conditioned media from control untreated cells or cells treated with a low (0.3 ng/ml) or high (10 ng/ml) doses of HGF. Analysis
was performed at least 3 times in triplicates *p < 0.05. Panel b. Proliferation of lung cancer cells in the presence of the adenosine receptor
inhibitor caffeine and the P2X receptor inhibitor iso-PPADS. The experiment was performed three times in triplicate. *p < 0.05
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One of the most challenging clinical problems is the
tumor recurrence and metastasis of cancer cells that sur-
vive standard treatment [1, 13, 24]. To explain these phe-
nomena, we have proposed that one of the unwanted side
effects of radiochemotherapy is the induction of a pro-
metastatic microenvironment in normal tissues that are
damaged by the treatment, due to an increase in certain
peptide- and lipid-based chemottractants [1, 3, 4, 13]. In
parallel, we have hypothesized that “leaky” cells damaged
by radiochemotherapy also release nucleotides that, as
demonstrated in the past, are potent chemotactic factors
for both normal [9, 25] and malignant cells [16, 18].
In support of a role of purinergic signaling in cancero-
genesis, it is well known that malignant tumors promote
strong inflammatory reactions together with necrosis,
and nucleotides may leak from damaged cells into the
extracellular medium or even be released by specific
pathways as part of tumor cell metabolism and anti-
tumor protection mechanisms [26–29]. What is also im-
portant, nucleotides may be released from the damaged
cells in response to radiochemotherapy, as shown in this
paper. In fact, we found an increase in ATP level in irra-
diated murine tissues, including BM and liver, which are
known sites for cancer metastasis. It has also been re-
ported that nucleotides may be released from cells stim-
ulated by the fifth complement cleavage fragment, the
anaphylotoxin C5a [9], and it is well known that the
complement cascade is activated in cancer patients [30,
31]. In our studies, we found that HGF may also in-
crease the secretion of ATP from LC cells, and HGF,
along with C5a, is upregulated in response to radioche-
motherapy [13, 32]. The question remains whether, in
addition to C5a and HGF, other factors that are released
in tissues in response to anti-cancer treatment such as
certain chemokines [13] or bioactive lipids [3, 4] also in-
crease the release of nucleotides from target cells, but
this requires further studies.
In our work, we focused mainly on the biological ef-
fects of ATP, ADP, AMP, and adenosine, which are well-
established ligands for G-protein coupled P1 and P2Y
receptors and ligand-gated ion channel P2X receptors
[23]. While P1 receptors are activated by adenosine and
A1 receptor subtypes also by AMP [33], P2X receptors
are activated by ATP, and P2Y receptors respond to
ATP, ADP and UTP [34]. In our studies, we demon-
strated that all of these nucleotides stimulate human LC
cells. We also found responsiveness of LC cells to TTP,
CTP, and GTP. Despite some suggestions that these nu-
cleotides may also stimulate some P2X receptors, we
cannot exclude that observed effect is due to receptor
independent cell stimulation. As support of such hy-
pothesis, similar phenomenons were already described
for ATP [11] and adenosine [35]. However, we focusedour current work on the most relevant EXNs and nu-
cleoside, which are ATP, ADP, AMP, and adenosine.
We learned that human NSCLC and SCLC cells ex-
press several functional purinergic receptors. Stimulation
by EXNs promoted migration and adhesion of LC cells.
These functional responses of LC to nucleotides are sup-
ported by the activation of intracellular pathways, in-
cluding MAPKp42/44 and AKT phosphorylation, as well
as [Ca2+]i transients.
Nucleotides have already been reported to stimulate
proliferation of some malignant cells, including colon
adenocarcinoma and melanoma cells [36, 37]. To our
surprise, however, we found that, if added to LC cell cul-
tures, nucleotides did not stimulate their growth. On the
other hand, we detected ATP in conditioned media har-
vested from LC cells, and inhibition of purinergic signal-
ing in these cells by iso-PPADS and caffeine negatively
affected their proliferation. This suggests the involve-
ment of autocrine signaling axes in the proliferation of
LC cell lines. In support of a role for autocrine puriner-
gic signaling in regulating the biology of LC cells, auto-
crine signaling via release of ATP and activation of the
P2X7 receptor was found by another group to enhance
the motility of human LC cells [17].
Nevertheless, data on the effect of nucleotides and nu-
cleosides on the proliferation of LC cells are somewhat
controversial. For example, it has been reported that
treatment of A549 cells with adenosine results in their
senescence, both in vitro and in vivo, through induction
of cell cycle arrest and senescence in a p53/p21-
dependent manner [38]. A similar effect has been ob-
served after exposure of the PC14 lung adenocarcinoma
cell line to ATP [39]. However, in another report, ATP
stimulation of P2Y receptors increased the proliferation
of human lung epithelial tumor cells [21]. These differ-
ences may be explained by the much higher concentra-
tions of ATP employed in those studies compared with
the concentrations that we used in our work.
It is well known that EXNs may affect different aspects
of LC biology. For example, ATP was found to sensitize
LC cells to cisplatin-induced apoptosis [40] and enhance
the antitumor effect of etoposide in PC14 and A549 LC
cells [39]. Moreover, it has been reported that extracellu-
lar ATP may be internalized by cancer cells by micropi-
nocytosis, which induces an increase in intracellular
ATP and drug resistance [11]. It was also shown that
ATP- or UTP-mediated activation of P2Y2 induced can-
cer cell invasion through increased production of VEGF
by cancer cells [41] and that adenosine receptors have
been found to regulate VEGF expression under hypoxic
environment in different tissues [42]. On the other hand,
EXNs are potent chemoattractants for mesenchymal
stromal cells and thus may attract these cells and pro-
mote stromalization of the growing tumor [43].
AB
C
Fig. 7 External nucleotide levels create a pro-metastatic microenvironment in irradiated organs. Panel a. Detection of human lung cancer cells
(HTB177) in liver, lung, and BM of mice irradiated and then inoculated with LC cells. HTB177 cells before transplant were pretreated with PSB603
(1 μM) or vehicle. Five mice were employed per group, and results are shown as means ± SEM. *p < 0.05. Panel b. Detection of human lung
cancer cells (HTB177) in liver, lung, and BM of mice irradiated and then inoculated with LC cells. HTB177 cells before transplant were pretreated with
iso-PPADS (10 μM) or vehicle. Five mice were employed per group, and results are shown as means ± SEM. *p < 0.05. Panel c. Radiochemotherapy
induces release of EXNs that may be reponsible for the metastatic spread of LC cells that survived the initial tretament
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genitors and thereby promote tumor vascularization
[44]. Altogether, given these data, purine and pyrimidine
nucleotides can be considered crucial orchestrators of
both directly and indirectly regulated pro-metastatic po-
tential of tumor cells.
What is most important in our report is that, by
employing pro-metastatic assays in vitro and in vivo, we
have demonstrated for the first time that purinergic sig-
naling may be an attractive target for small molecule an-
tagonists of purinergic receptors to inhibit the metastatic
spread of LC cells. Our results employing receptor antago-
nists lend further support to this concept. On the other
hand, it is known that degradation of EXNs in the
extracellular space is regulated by enzymatic cascades, in-
cluding ectonucleoside triphosphate diphosphohydrolases
(E-NTPDase 1, also known as CD39; E-NTPDases 2, 3,
and 8), ectonucleotide pyrophosphatases/phosphodiester-
ases (E-NPPs), ecto-alkaline phosphatases, and ecto-5′-
nucleotidase (also known as CD73), which degrade
nucleotides (e.g. ATP, ADP, and AMP), finally yielding nu-
cleosides (e.g. adenosine) and thereby regulating activ-
ity levels of the various P2 and P1 receptors [45–47].
In addition to purinergic receptors, these enzymes are
potential targets for small molecule inhibitors to con-
trol migration and metastasis of LC cells. This is of
particular importance, since, as mentioned above, the
concentration of EXNs in tumor tissue could be very
high [11, 48]. However, the evidence supporting a
functional role of ectonucleotidases in purinergic sig-
naling varies considerably between enzyme species
and thus should be taking into consideration when
looking for possible anti-cancer targets [46, 47].
We are aware that the results that we generated with
established human LC cell lines need to be verified with
LC patient primary cells. It will be important to establish
whether the pattern of purinergic receptor expression
has prognostic value and whether it correlates with more
malignant and metastatic phenotypes.
Conclusion
EXNs are novel pro-metastatic factors released during
radiochemotherapy (Fig. 1a and b), and inhibition of
their pro-metastatic effects, which are mediated by puri-
nergic signaling, could become a novel and important
part of anti-metastatic treatment. The results reported
here for LC cell lines may also be relevant for other can-
cers, as EXNs have been reported to stimulate several
other types of cancer cells [16, 18, 49].
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